Personalized volume de-escalated elective nodal irradiation in oropharyngeal squamous cell carcinoma (DeEscO): a study protocol.
Esmée L Looman, Yoel Pérez Haas, Roman Ludwig...
https://pubmed.ncbi.nlm.nih.gov/42200110/Actively Recruiting
Led by University of Zurich · Updated on 2026-10-08
120
Participants Needed
7
Research Sites
52 weeks
Total Duration
This research focuses on oropharyngeal squamous cell carcinoma SCC of all stages and explores a personalized approach to reduce the elective clinical target volume CTV in radiotherapy. The goal is to decrease radiation-related toxicity by tailoring treatment volumes based on individual patient risk factors and lymph node involvement. The study evaluates the safety of this de-escalated target volume by monitoring the rate of cancer recurrence outside the treated areas. Participants receive radiotherapy with a personalized reduction of the elective nodal irradiation volume guided by a statistical model. This model predicts the probability of hidden lymph node metastases using patient-specific data such as tumor stage, lymph node involvement, and tumor location. The treatment involves primary chemoradiotherapy with individualized target volumes created and reviewed by clinicians to ensure safety and consistency. During the study, patients undergo assessments including imaging scans like FDG-PET or contrast-enhanced MRI before treatment. Researchers monitor outcomes such as nodal recurrence rates up to three years after radiotherapy, loco-regional control, progression-free survival, overall survival, and treatment-related toxicity. Quality of life related to head and neck symptoms is also evaluated at multiple time points. Participation lasts through treatment and includes follow-up visits for up to three years to assess long-term effects and safety.
CONDITIONS
Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma
P
Panagiotis Balermpas, MD
D
Debra Lauer, MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Zurich
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Duration of radiotherapy treatment
Participants receive personalized volume-reduced elective nodal radiotherapy based on individual risk profiles.
Duration - Up to 3 years after radiotherapy
Participants are monitored for recurrence, survival, toxicity, and quality of life for up to 3 years after treatment.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Esmée L Looman, Yoel Pérez Haas, Roman Ludwig...
https://pubmed.ncbi.nlm.nih.gov/42200110/University of Zurich
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborating Sponsor